BioCentury
ARTICLE | Clinical News

Prosensa slides on analyst note on DMD data

August 16, 2013 11:38 PM UTC

Prosensa Holding N.V. (NASDAQ:RNA) slipped $2.29 to $26.25 on Friday after an analyst said newly released data suggest a "substantial number" of Duchenne muscular dystrophy (DMD) patients "may not be getting a meaningful drug effect" with Prosensa's drisapersen ( PRO051). Baird's Brian Skorney said about 28%-41% of patients in the Phase IIb DMD114117 trial were "devoid of a pharmacologic effect" with drisapersen as measured by dystrophin response. He said there is "substantial variability in individual patients to the extent that there appear to be pharmacological responders and non-responders."

Prosensa partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) made the additional data available on its clinical trial (see BioCentury Extra, April 10). ...